Want to see OTLC full AI Analyst Report?
Top Page
Oncotelic Therapeutics
(OTC:OTLC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.03
▲(3.33% Upside)
Action:Reiterated
Date:08/17/26
The score is primarily pressured by weak financial performance (minimal recurring revenue, persistent operating losses, and ongoing cash burn with low earnings quality) and dilution/financing risk from recent convertible funding. Technicals are neutral-to-weak with limited momentum, and valuation metrics provided do not support an earnings-based or income-driven case.
Positive Factors
Moderate Recent Leverage
Moderate recent leverage provides some solvency support and may reduce immediate balance-sheet pressure. However, historical periods of materially higher leverage and volatile returns indicate that this strength is not yet consistently established.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow shows that the business is not self-funding. Continued cash burn increases dependence on external capital, constrains investment flexibility, and makes durable value creation reliant on successful development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Moderate Recent Leverage
Moderate recent leverage provides some solvency support and may reduce immediate balance-sheet pressure. However, historical periods of materially higher leverage and volatile returns indicate that this strength is not yet consistently established.
Read all positive factors
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.87M
Dividend YieldN/A
Average Volume (3M)410.07K
Price to Earnings (P/E)<0.1
Beta (1Y)-0.06
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding457,512,800
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oncotelic Therapeutics Business Overview & Revenue Model
Company Description
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound de...
Oncotelic Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
45
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 250.00K | 0.00 | 0.00 | 70.00K | 0.00 | 0.00 |
| Gross Profit | 250.00K | 0.00 | 0.00 | 70.00K | -12.84K | -61.51K |
| EBITDA | -499.93B | 198.05B | -3.55M | -7.16M | -5.60M | -9.06M |
| Net Income | 247.50M | 249.28M | -4.52B | -7.90M | 17.82M | -11.39M |
Balance Sheet | ||||||
| Total Assets | 10.00T> | 10.00T> | 26.68M | 30.01M | 36.12M | 23.61M |
| Cash, Cash Equivalents and Short-Term Investments | 186.01B | 88.86B | 86.13K | 170.41K | 241.45K | 568.77K |
| Total Debt | 16.16T | 16.27T | 13.09M | 12.57M | 11.26M | 8.99M |
| Total Liabilities | 10.00T> | 10.00T> | 19.20M | 18.40M | 16.92M | 15.45M |
| Stockholders Equity | 10.00T> | 10.00T> | 8.25M | 12.13M | 19.41M | 7.96M |
Cash Flow | ||||||
| Free Cash Flow | -1.52M | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Operating Cash Flow | -1.52M | -1.38T | -740.27K | -1.32M | -1.45M | -4.43M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 1.62M | 1.39T | 656.00K | 1.25M | 1.13M | 4.53M |
Oncotelic Therapeutics Technical Analysis
Negative
0.03
Price Trends
0.04
Negative
0.04
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
40.16
Neutral
14.04
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLC, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of 14.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLC.
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics disclosed 38 risk factors in its most recent earnings report. Oncotelic Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncotelic Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $44.73M | 0.77 | 940.81% | ― | -48.76% | -3.02% | |
47 Neutral | $46.28M | -1.71 | -35.78% | ― | ― | -43.60% | |
46 Neutral | $27.87M | -1.35 | -456.35% | ― | ― | 9.68% | |
44 Neutral | $20.08M | -0.43 | 4092.98% | ― | ― | 15.37% | |
44 Neutral | $85.76M | -2.19 | -211.15% | ― | ― | -7.28% | |
41 Neutral | $14.87M | 0.05 | -38.38% | ― | ― | ― |
* Healthcare Sector Average
OTLC
Oncotelic Therapeutics
0.03
-0.02
-41.51%
GRCE
Grace Therapeutics
2.15
-0.84
-28.09%
LTRN
Lantern Pharma
2.18
-1.88
-46.31%
CALC
CalciMedica
0.59
-2.14
-78.50%
ELUT
Elutia
1.00
-1.33
-57.08%
MAIA
MAIA Biotechnology, Inc.
1.39
-0.13
-8.55%
Oncotelic Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Announces New Convertible Note Financing Agreement
Negative
Aug 4, 2026
On August 3, 2026, Oncotelic Therapeutics entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, issuing a $178,410 convertible promissory note with a 12% original issue discount and 12% annual interest. The note can be con...
Business Operations and StrategyExecutive/Board Changes
Oncotelic Therapeutics Grants Performance-Based Restricted Stock Units
Positive
Jul 15, 2026
On July 10, 2026, Oncotelic Therapeutics, Inc. approved the grant of 17,796 restricted stock units to its directors, officers, employees, and advisors, each RSU convertible into one share of Series A Convertible Preferred Stock and ultimately into...
Business Operations and StrategyRegulatory Filings and Compliance
Oncotelic Therapeutics Provides Internal Corporate Update Presentation
Neutral
Jul 15, 2026
On July 13, 2026, Oncotelic Therapeutics, Inc. delivered a corporate presentation to its employees, directors, officers and advisors, outlining company information in a formal setting. The materials were furnished to stakeholders through a Form 8-...
Business Operations and StrategyPrivate Placements and Financing
Oncotelic Therapeutics Enters New Convertible Note Financing
Neutral
Jun 29, 2026
On June 23, 2026, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a $178,410 convertible promissory note carrying a 12% original issue discount and 12% annual interest, maturing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.